Positive interim data for Ixaka’s lead ‘multi-cell’ therapy
The independent data monitoring committee (DMC) has recommended continuation of the Phase III trial
Read More
Tag: Ixaka
UK biotech Ixaka scores additional funding for cell and gene therapy research
Lead asset REX-001 is in Phase III development for chronic limb-threatening ischaemia
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
